Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis

Archives of Dermatology

Volumn 141, Issue 6, 2005, Pages 683-687

  Quinn, Adam M ^a   Brown, Kimberly ^a   Bonish, Brian K ^a   Curry, Jonathan ^a   Gordon, Kenneth B ^b   Sinacore, James ^b   Gamelli, Richard ^a   Nickoloff, Brian J ^a,c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; GLUCOSE;

BODY SURFACE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HEART RATE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDICAL RECORD; MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SKIN BIOPSY; SKIN INFLAMMATION; SURVIVAL; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; ADULT; AGED; ARTICLE; BURN; COMPARATIVE STUDY; FEMALE; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; RISK ASSESSMENT; SURVIVAL RATE; UNITED STATES; UNIVERSITY HOSPITAL;

ADULT; AGED; BIOPSY, NEEDLE; BURN UNITS; CALIFORNIA; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HOSPITAL MORTALITY; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 21844472796     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.141.6.683     Document Type: Review

References (25)

1. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355-361.
2. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102:28S-30S.
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.
4. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol. 1990;23:1039-1058.
5. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil. 2000;21:199-204.
6. Aurelian L, Kokuba H, Burnett JW. Understanding the pathogenesis of HSV-associated erythema multiforme. Dermatology. 1998;197:219-222.
7. Aurelian L, Ono F, Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J. 2003;9:1.
8. Kokuba H, Aurelian L, Burnett J. Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factoralpha in drug-induced erythema multiforme lesions. J Invest Dermatol. 1999;113:808-815.
9. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162:1515-1520.
10. Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135:6-11.
11. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153.
12. Qin JZ, Chaturvedi V, Denning MF, et al. Regulation of apoptosis by p53 in UV-irradiated human epidermis, psoriatic plaques and senescent keratinocytes. Oncogene. 2002;21:2991-3002.
13. Soltysik RC, Yarnold PR. ODA 1.0: Optimal Data Analysis for DOS. Chicago, Ill: Optimal Data Analysis Inc; 1993.
14. Austin LM, Coven TR, Bhardwaj N, Steinman R, Krueger JG. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. J Cutan Pathol. 1998;25:79-88.
15. Weedon D. Skin Pathology. New York, NY: Churchill Livingstone; 2002:45.
16. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87-96.
17. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81-88.
18. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473-478.
19. Roujeau JC. Treatment of severe drug eruptions. J Dermatol. 1999;26:718-722.
20. Roujeau JC, Moritz S, Guillaume JC, et al. Lymphopenia and abnormal balance of T-lymphocyte subpopulations in toxic epidermal necrolysis. Arch Dermatol Res. 1985;277:24-27.
21. Merot Y, Gravallese E, Guillen FJ, Murphy GF. Lymphocyte subsets and Langerhans' cells in toxic epidermal necrolysis: report of a case. Arch Dermatol. 1986;122:455-458.
22. Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol. 1997;19:127-132.
23. Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Pierard GE. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol. 2000;22:413-417.
24. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
25. Paquet P, Pierard GE. Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med. 2002;10:145-147.